ATAI Life Sciences Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 83

Employees

  • Stock Symbol
  • ATAI

Stock Symbol

  • Investments
  • 23

  • Share Price
  • $1.60
  • (As of Wednesday Closing)

ATAI Life Sciences General Information

Description

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Contact Information

Website
www.atai.life
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • Wallstrasse 16
  • 10179 Berlin
  • Germany
+49 089 00000000

ATAI Life Sciences Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ATAI Life Sciences Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.60 $1.64 $1.02 - $2.85 $268M 167M 919K -$0.21

ATAI Life Sciences Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 168,311 43,986 158,853 803,177
Revenue 277 314 233 20,376
EBITDA (30,631) (38,158) (134,639) (136,759)
Net Income (33,803) (40,224) (152,385) (167,808)
Total Assets 269,121 293,478 305,441 414,166
Total Debt 20,807 19,142 15,341 743
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ATAI Life Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ATAI Life Sciences‘s full profile, request access.

Request a free trial

ATAI Life Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health d
Drug Discovery
Berlin, Germany
83 As of 2023
00000
00000000000 00000

000000

sectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore m
0000000000000
New York, NY
000 As of 0000
00000
00000000 00000

000000

laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repreh
0000 000000000
Boston, MA
000 As of 0000
00000
000.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ATAI Life Sciences Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Axsome Therapeutics Corporation New York, NY 000 00000 00000000 00000
Karuna Therapeutics Formerly VC-backed Boston, MA 000 00000 000000&0 00000
SAGE Therapeutics Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
You’re viewing 3 of 3 competitors. Get the full list »

ATAI Life Sciences Patents

ATAI Life Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240116896-A1 Heteroatom substituted cyclic and alkyl amines as activators of serotonin receptors Pending 06-Sep-2022 0000000000
US-20230270714-A1 Salvinorin compositions Pending 08-Dec-2021 0000000000
US-20230100844-A1 Ibogaine combination treatment Inactive 10-Sep-2021 00000000000
US-11660419-B2 Systems, devices, and methods for generating and manipulating objects in a virtual reality or multi-sensory environment to maintain a positive state of a user Active 16-Jul-2021 000000000 00
US-20230248936-A1 Systems, devices, and methods for generating and manipulating objects in a virtual reality or multi-sensory environment to maintain a positive state of a user Pending 16-Jul-2021 A61M21/02
To view ATAI Life Sciences’s complete patent history, request access »

ATAI Life Sciences Executive Team (15)

Name Title Board Seat
Florian Brand Chief Executive Officer & Co-Founder
Srinivas Rao Ph.D Chief Executive Officer & Founder
Anne Johnson Chief Financial Officer
Sahil Kirpekar Executive
Amber Ardieta Executive Assistant, Research & Development
You’re viewing 5 of 15 executive team members. Get the full list »

ATAI Life Sciences Board Members (11)

Name Representing Role Since
Andrea Smiley ATAI Life Sciences Board Member 000 0000
Christian Angermayer Presight Capital Chairman & Board Member 000 0000
Laurent Fischer MD Self Board Member 000 0000
Michael Auerbach Canaccord Genuity Board Member 000 0000
Raymond Sanchez Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

ATAI Life Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ATAI Life Sciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ATAI Life Sciences‘s full profile, request access.

Request a free trial

ATAI Life Sciences Investments & Acquisitions (23)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Intelgenx Technologies 27-May-2024 0000000000 Drug Delivery 00000 000
Beckley Psytech 03-Jan-2024 00000 0000 000.00 Drug Discovery 0000000 0
Intelgenx Technologies 05-Dec-2023 0000 00.000 Drug Delivery 00000000
Ibogaine 01-Nov-2023 0000000000 Drug Discovery 0000000 0
DemeRx 01-Oct-2023 Merger/Acquisition Pharmaceuticals
You’re viewing 5 of 23 investments and acquisitions. Get the full list »

ATAI Life Sciences Subsidiaries (4)

Company Name Industry Location Founded
Atai Life Sciences Uk Other Commercial Services London, United Kingdom 2021
Psyber Therapeutic Devices New York, NY 0000
Recognify Life Sciences Drug Discovery Berlin, Germany 0000
DemeRx Pharmaceuticals Miami, FL
To view ATAI Life Sciences’s complete subsidiaries history, request access »

ATAI Life Sciences ESG

Risk Overview

Risk Rating

Updated April, 11, 2024

33.41 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

00.00

Percentile

To view ATAI Life Sciences’s complete esg history, request access »

ATAI Life Sciences Exits (4)

Company Name Exit Date Exit Type Exit Size Status Buyers
PsyProtix 17-Feb-2021 00000 0000000 00000 Completed
  • 2 buyers
COMPASS Pathways 17-Apr-2020 00000 00000 00 000.00 Completed
  • 21 buyers
COMPASS Pathways 20-Sep-2018 00000 00000 00 000.00 Completed
  • 5 buyers
COMPASS Pathways Later Stage VC 000.00 Completed
To view ATAI Life Sciences’s complete exits history, request access »

ATAI Life Sciences FAQs

  • When was ATAI Life Sciences founded?

    ATAI Life Sciences was founded in 2018.

  • Who is the founder of ATAI Life Sciences?

    Florian Brand, Srinivas Rao Ph.D, and Lars Wilde are the founders of ATAI Life Sciences.

  • Who is the CEO of ATAI Life Sciences?

    Florian Brand and Srinivas Rao Ph.D are the CEOs of ATAI Life Sciences.

  • Where is ATAI Life Sciences headquartered?

    ATAI Life Sciences is headquartered in Berlin, Germany.

  • What is the size of ATAI Life Sciences?

    ATAI Life Sciences has 83 total employees.

  • What industry is ATAI Life Sciences in?

    ATAI Life Sciences’s primary industry is Drug Discovery.

  • Is ATAI Life Sciences a private or public company?

    ATAI Life Sciences is a Public company.

  • What is ATAI Life Sciences’s stock symbol?

    The ticker symbol for ATAI Life Sciences is ATAI.

  • What is the current stock price of ATAI Life Sciences?

    As of 17-Jul-2024 the stock price of ATAI Life Sciences is $1.60.

  • What is the current market cap of ATAI Life Sciences?

    The current market capitalization of ATAI Life Sciences is $268M.

  • What is ATAI Life Sciences’s current revenue?

    The trailing twelve month revenue for ATAI Life Sciences is $277K.

  • Who are ATAI Life Sciences’s competitors?

    Axsome Therapeutics, Karuna Therapeutics, and SAGE Therapeutics are competitors of ATAI Life Sciences.

  • What is ATAI Life Sciences’s annual earnings per share (EPS)?

    ATAI Life Sciences’s EPS for 12 months was -$0.21.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »